JP2022538299A5 - - Google Patents

Info

Publication number
JP2022538299A5
JP2022538299A5 JP2021577424A JP2021577424A JP2022538299A5 JP 2022538299 A5 JP2022538299 A5 JP 2022538299A5 JP 2021577424 A JP2021577424 A JP 2021577424A JP 2021577424 A JP2021577424 A JP 2021577424A JP 2022538299 A5 JP2022538299 A5 JP 2022538299A5
Authority
JP
Japan
Prior art keywords
substituted
unsubstituted
group
compound
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021577424A
Other languages
English (en)
Japanese (ja)
Other versions
JP7787635B2 (ja
JP2022538299A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/040153 external-priority patent/WO2020264509A1/en
Publication of JP2022538299A publication Critical patent/JP2022538299A/ja
Publication of JP2022538299A5 publication Critical patent/JP2022538299A5/ja
Priority to JP2025000024A priority Critical patent/JP2025060984A/ja
Application granted granted Critical
Publication of JP7787635B2 publication Critical patent/JP7787635B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021577424A 2019-06-27 2020-06-29 Cns障害を治療するための組成物及び方法 Active JP7787635B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025000024A JP2025060984A (ja) 2019-06-27 2025-01-05 Cns障害を治療するための組成物及び方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962867618P 2019-06-27 2019-06-27
US62/867,618 2019-06-27
PCT/US2020/040153 WO2020264509A1 (en) 2019-06-27 2020-06-29 Compositions and methods for treating cns disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025000024A Division JP2025060984A (ja) 2019-06-27 2025-01-05 Cns障害を治療するための組成物及び方法

Publications (3)

Publication Number Publication Date
JP2022538299A JP2022538299A (ja) 2022-09-01
JP2022538299A5 true JP2022538299A5 (cg-RX-API-DMAC7.html) 2023-07-07
JP7787635B2 JP7787635B2 (ja) 2025-12-17

Family

ID=71728947

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021577424A Active JP7787635B2 (ja) 2019-06-27 2020-06-29 Cns障害を治療するための組成物及び方法
JP2025000024A Pending JP2025060984A (ja) 2019-06-27 2025-01-05 Cns障害を治療するための組成物及び方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025000024A Pending JP2025060984A (ja) 2019-06-27 2025-01-05 Cns障害を治療するための組成物及び方法

Country Status (13)

Country Link
US (1) US12552829B2 (cg-RX-API-DMAC7.html)
EP (1) EP3990469A1 (cg-RX-API-DMAC7.html)
JP (2) JP7787635B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220038680A (cg-RX-API-DMAC7.html)
CN (1) CN114391019A (cg-RX-API-DMAC7.html)
AR (1) AR119305A1 (cg-RX-API-DMAC7.html)
AU (1) AU2020302748A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021026462A2 (cg-RX-API-DMAC7.html)
CA (1) CA3143509A1 (cg-RX-API-DMAC7.html)
IL (1) IL289172A (cg-RX-API-DMAC7.html)
MX (3) MX2021015942A (cg-RX-API-DMAC7.html)
TW (1) TWI896547B (cg-RX-API-DMAC7.html)
WO (1) WO2020264509A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS62761B1 (sr) 2012-08-21 2022-01-31 Sage Therapeutics Inc Alopregnanolon za lečenje refraktornog epileptičkog statusa
SMT202100509T1 (it) 2013-04-17 2021-11-12 Sage Therapeutics Inc Steroide di c21-n-pirazolile 19-nor c3,3-disostituito per l'uso in terapia
US10246482B2 (en) 2014-06-18 2019-04-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
WO2016082789A1 (en) 2014-11-27 2016-06-02 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
WO2018013613A1 (en) 2016-07-11 2018-01-18 Sage Therapeutics, Inc. C17, c20, and c21 substituted neuroactive steroids and their methods of use
TW202604538A (zh) 2016-08-23 2026-02-01 美商賽吉醫療公司 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇
US20200291059A1 (en) 2017-12-08 2020-09-17 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
JP7670626B2 (ja) 2019-05-31 2025-04-30 セージ セラピューティクス, インコーポレイテッド 神経刺激性ステロイド及びその組成物
JP7787635B2 (ja) * 2019-06-27 2025-12-17 セージ セラピューティクス, エルエルシー Cns障害を治療するための組成物及び方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2969M (fr) 1963-05-22 1964-11-30 Roussel Uclaf Nouveau médicament notamment pour le traitement des spasmes d'origine coronarienne on viscérale.
ES432106A1 (es) 1973-11-30 1976-11-01 Schering Ag Procedimiento para la preparacion de d-homo-20-cetopregna- nos.
IL48628A0 (en) 1974-12-23 1976-02-29 Schering Ag D-homo-20-keto-pregnanes and process for their manufactur
GB1570394A (en) 1976-01-06 1980-07-02 Glaxo Lab Ltd 11-acyloxy-3-hydroxy steroids
US4060295A (en) 1976-03-15 1977-11-29 Molex Incorporated Zero insertion force printed circuit board edge connector assembly
GB1581234A (en) 1976-04-05 1980-12-10 Glaxo Operations Ltd 11a - amino - 3a - hydroxysteroids
GB1581235A (en) 1977-04-04 1980-12-10 Glaxo Operations Ltd 11a-amino-3a-hydroxy-steroids
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
BR9509764A (pt) 1994-11-23 1998-07-07 Cocensys Inc Série androstano e pregnano para modulação alostérica de receptor de gaba
AU3967297A (en) 1996-08-01 1998-02-25 Cocensys, Inc. Use of gaba and nmda receptor ligands for the treatment of migraine headache
WO2005105822A2 (en) 2004-04-23 2005-11-10 Euro-Celtique S.A. 3-alpha-hydroxy 21-n- heteroaryl-pregnane derivatives for modulation of brain excitability and a process for the production thereof
CN101585862B (zh) 2008-05-20 2014-12-17 梅克芳股份公司 甾族化合物
HUE062616T2 (hu) 2011-09-08 2023-11-28 Sage Therapeutics Inc Neuroaktív szteroidok, készítmények és alkalmazásaik
SMT202100509T1 (it) 2013-04-17 2021-11-12 Sage Therapeutics Inc Steroide di c21-n-pirazolile 19-nor c3,3-disostituito per l'uso in terapia
SI3705488T1 (sl) 2014-05-29 2022-10-28 Sage Therapeutics, Inc. Nevroaktivni steroidi, sestavki in uporaba le-teh
MY190408A (en) * 2014-10-16 2022-04-21 Sage Therapeutics Inc Compositions and methods for treating cns disorders
WO2017049044A1 (en) 2015-09-16 2017-03-23 Bartolucci Giampiero Ursodeoxycholic acid and brain disorders
PH12018501923B1 (en) 2016-03-08 2024-06-28 Sage Therapeutics Inc Neuroactive steroids, compositions, and uses thereof
CA3030420C (en) * 2016-07-11 2025-11-18 Sage Therapeutics, Inc. C7, C12 AND C16 SUBSTITUTED NEUROACTIVE STEROIDS AND ASSOCIATED METHODS OF USE
AU2018290348B2 (en) * 2017-06-23 2024-04-04 Ayikoe-Guy MENSAH-NYAGAN Treatment of neuropsychiatric disorders with neurosteroids and analogues thereof
WO2019041078A1 (en) 2017-08-28 2019-03-07 Zhejiang Jiachi Pharmaceutical Development Ltd. ASYMMETRIC SYNTHESIS AND USES OF COMPOUNDS IN TREATMENT OF DISEASES
EP3678670A1 (en) * 2017-09-07 2020-07-15 Sage Therapeutics, Inc. Neuroactive steroids and their methods of use
EP3728285B1 (en) * 2017-12-22 2026-04-08 Sage Therapeutics, LLC Compositions and methods for treating cns disorders
US12139508B2 (en) 2018-02-11 2024-11-12 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Steroid derivative regulators, method for preparing the same, and uses thereof
IL312610B2 (en) * 2018-12-05 2026-05-01 Sage Therapeutics Llc Neuroactive steroids and methods of using them
CN111410678B (zh) 2019-01-08 2023-02-28 成都康弘药业集团股份有限公司 甾体类化合物、用途及其制备方法
WO2020210116A1 (en) * 2019-04-08 2020-10-15 Athenen Therapeutics, Inc. Steroids with altered pharmacokinetic properties and methods of use thereof
WO2020210117A1 (en) * 2019-04-08 2020-10-15 Athenen Therapeutics, Inc. Steroids with altered pharmacokinetic properties and methods of use thereof
JP7670626B2 (ja) 2019-05-31 2025-04-30 セージ セラピューティクス, インコーポレイテッド 神経刺激性ステロイド及びその組成物
BR112021026447A2 (pt) 2019-06-27 2022-04-12 Sage Therapeutics Inc Composições e métodos para tratamento de distúrbios de cns
CA3143545A1 (en) 2019-06-27 2020-12-30 Sage Therapeutics, Inc. Compounds for treating cns disorders
JP7787635B2 (ja) * 2019-06-27 2025-12-17 セージ セラピューティクス, エルエルシー Cns障害を治療するための組成物及び方法
EP4251634A1 (en) * 2020-11-25 2023-10-04 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders

Similar Documents

Publication Publication Date Title
JP2022538301A5 (cg-RX-API-DMAC7.html)
JP2022510683A5 (cg-RX-API-DMAC7.html)
JP2022538300A5 (cg-RX-API-DMAC7.html)
JP2022516469A5 (cg-RX-API-DMAC7.html)
JP4344235B2 (ja) タキソール増強剤化合物
JP2022532706A5 (cg-RX-API-DMAC7.html)
JP2021514001A5 (cg-RX-API-DMAC7.html)
RU2020123151A (ru) Антагонисты tlr7/8 и их применение
JPWO2023042879A5 (cg-RX-API-DMAC7.html)
JP2018502891A5 (cg-RX-API-DMAC7.html)
JP2023119042A5 (cg-RX-API-DMAC7.html)
JP2023518411A5 (cg-RX-API-DMAC7.html)
JP2019512485A5 (cg-RX-API-DMAC7.html)
JP2016534134A5 (cg-RX-API-DMAC7.html)
RU2017145650A (ru) Ингибиторы тирозинкиназы брутона
SI2824100T1 (en) 1,2,5-oxadiazoles as inhibitors of indolamine 2,3-dioxygenase
JP2022504607A5 (cg-RX-API-DMAC7.html)
JP2002524463A5 (cg-RX-API-DMAC7.html)
JP2008505874A5 (cg-RX-API-DMAC7.html)
JP2006506455A5 (cg-RX-API-DMAC7.html)
JP2022525069A5 (cg-RX-API-DMAC7.html)
JP2023504542A5 (cg-RX-API-DMAC7.html)
JP2022511477A5 (cg-RX-API-DMAC7.html)
AU2002238855B2 (en) N-phenylarylsulfonamide compound, drug containing the compound as active ingredient, intermediate for the compound, and processes for producing the same
RU2016111138A (ru) Гетероциклические соединения и способы их применения